Satellos Bioscience (NASDAQ:MSLE) Releases Earnings Results

Satellos Bioscience (NASDAQ:MSLE) announced its quarterly earnings data on Friday. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.11), Zacks reports.

Satellos Bioscience Stock Performance

Satellos Bioscience stock opened at $6.19 on Friday. The stock has a market capitalization of $95.70 million, a PE ratio of -5.16 and a beta of 1.10. Satellos Bioscience has a twelve month low of $4.53 and a twelve month high of $13.39.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Zacks Research raised shares of Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Weiss Ratings initiated coverage on Satellos Bioscience in a research report on Wednesday, February 11th. They issued a “sell (d-)” rating on the stock. Cantor Fitzgerald began coverage on Satellos Bioscience in a research report on Wednesday, March 11th. They set an “overweight” rating for the company. Finally, Wall Street Zen downgraded Satellos Bioscience to a “strong sell” rating in a research note on Saturday, March 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Satellos Bioscience has a consensus rating of “Hold”.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.